OptiBiotix Health (LSE:OPTI) Change In Working Capital : £0.70 Mil (TTM As of Jun. 2023)

View and export this data going back to 2011. Start your Free Trial

What is OptiBiotix Health Change In Working Capital?

OptiBiotix Health's change in working capital for the quarter that ended in Jun. 2023 was £0.09 Mil.

OptiBiotix Health's change in working capital for the fiscal year that ended in Dec. 2022 was £1.02 Mil.

It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement. Not by calculating the number changes in each periods' working capital (Total Current Assets minus Total Current Liabilities).

OptiBiotix Health Change In Working Capital Historical Data

The historical data trend for OptiBiotix Health's Change In Working Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

OptiBiotix Health Change In Working Capital Chart

OptiBiotix Health Annual Data

Trend

Jul10

Jul12

Nov14

Nov15

Nov16

Nov17

Nov18

Dec20

Dec21

Dec22

Change In Working Capital

Get a 7-Day Free Trial

0.06

-0.01

-0.20

-0.74

1.02

OptiBiotix Health Semi-Annual Data
	Jul12	Jan13	May14	Nov14	May15	Nov15	May16	Nov16	May17	Nov17	May18	Nov18	May19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23
Change In Working Capital	Get a 7-Day Free Trial															-0.42	-0.33	0.41	0.61	0.09

OptiBiotix Health Change In Working Capital Calculation

Change In Working Capital for the trailing twelve months (TTM) ended in Jun. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was £0.70 Mil.

Working Capital is a measure of a company's short term liquidity or its ability to cover short term liabilities. It is defined as the difference between a company's current assets and current liabilities.

Changes in Working Capital is reported in the cash flow statement since it is one of the major ways in which net income can differ from operating cash flow. It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement.

Use Wal-Mart Stores Inc (Jan 2014, Annual Data) as an example: Source: Wal-Mart Stores Inc 2014-01-31 10-K from SEC

Consolidated Statements of Cash Flows	Fiscal Years Ended	January 31,	(Amounts in millions)
Cash flows from operating activities:	2014	2013	2012
Changes in certain assets and liabilities, net of effects of acquisitions:
Receivables, net	(566)	(614)	(796)
Inventories	(1,667)	(2,759)	(3,727)
Accounts payable	531	1,061	2,687
Accrued liabilities	103	271	(935)
Accrued income taxes	(1,224)	981	994

For 2014-01-31, add all the items under 2014 collum together, Change in Working Capital was (566) + (1,667) + 531 + 103 + (1,224) = $ (2,823) Mil.

OptiBiotix Health Change In Working Capital Related Terms

Thank you for viewing the detailed overview of OptiBiotix Health's Change In Working Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

OptiBiotix Health (LSE:OPTI) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » OptiBiotix Health PLC (LSE:OPTI) » Definitions » Change In Working Capital

Comparable Companies

Traded in Other Exchanges

OPTI.GB:UK OB3:Germany

Address

Innovation Centre, Innovation Way, Heslington, York, GBR, YO10 5DG

Website

https://www.optibiotix.com

OptiBiotix Health PLC is engaged in the field of healthcare. As a life science company, its prime focus lies in researching the area of biotechnology. Its activities include the identification of microbial strains, compounds, and formulations for use in food ingredients, supplements, and active compounds that can impact human physiology, deriving potential health benefits. The company derives majority of the revenue from the sale of Functional Fibres. The company markets its products in the United Kingdom under trademark names such as OptiBiotix, SweetBiotix, and SkinBioTherapeutics.